BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014;120:1960-1967. [PMID: 24737347 DOI: 10.1002/cncr.28662] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
2 Kenner B, Chari ST, Kelsen D, Klimstra DS, Pandol SJ, Rosenthal M, Rustgi AK, Taylor JA, Yala A, Abul-Husn N, Andersen DK, Bernstein D, Brunak S, Canto MI, Eldar YC, Fishman EK, Fleshman J, Go VLW, Holt JM, Field B, Goldberg A, Hoos W, Iacobuzio-Donahue C, Li D, Lidgard G, Maitra A, Matrisian LM, Poblete S, Rothschild L, Sander C, Schwartz LH, Shalit U, Srivastava S, Wolpin B. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Pancreas 2021;50:251-79. [PMID: 33835956 DOI: 10.1097/MPA.0000000000001762] [Reference Citation Analysis]
3 Lucas AL, Malvezzi M, Carioli G, Negri E, La Vecchia C, Boffetta P, Bosetti C. Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. Clin Gastroenterol Hepatol. 2016;14:1452-1462.e4. [PMID: 27266982 DOI: 10.1016/j.cgh.2016.05.034] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 11.6] [Reference Citation Analysis]
4 Hung YP, Liu CJ, Hu YW, Chen MH, Li CP, Yeh CM, Chiou TJ, Chen TJ, Yang MH, Chao Y. Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study. Medicine (Baltimore) 2015;94:e1626. [PMID: 26402833 DOI: 10.1097/MD.0000000000001626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ, Navarro Almario JA, Brant A, Borges M, Ford M, Barkley T, He J, Weiss MJ, Wolfgang CL, Roberts NJ, Hruban RH, Klein AP, Goggins M. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. J Clin Oncol 2017;35:3382-90. [PMID: 28767289 DOI: 10.1200/JCO.2017.72.3502] [Cited by in Crossref: 167] [Cited by in F6Publishing: 90] [Article Influence: 41.8] [Reference Citation Analysis]
6 Crawley AS, O'Kennedy RJ. The need for effective pancreatic cancer detection and management: a biomarker-based strategy. Expert Rev Mol Diagn 2015;15:1339-53. [PMID: 26394703 DOI: 10.1586/14737159.2015.1083862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
7 Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV. Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer 2018;18:697. [PMID: 29945567 DOI: 10.1186/s12885-018-4573-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
8 Lee K, Yoo C, Kim KP, Park KJ, Chang HM, Kim TW, Lee JL, Lee W, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Invest New Drugs 2018;36:163-9. [PMID: 28782087 DOI: 10.1007/s10637-017-0497-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhu H, Welinsky S, Soper ER, Brown KL, Abul-Husn NS, Lucas AL. Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing. Pancreas 2021;50:602-6. [PMID: 33939675 DOI: 10.1097/MPA.0000000000001804] [Reference Citation Analysis]
10 Overbeek KA, Levink IJM, Koopmann BDM, Harinck F, Konings ICAW, Ausems MGEM, Wagner A, Fockens P, van Eijck CH, Groot Koerkamp B, Busch ORC, Besselink MG, Bastiaansen BAJ, van Driel LMJW, Erler NS, Vleggaar FP, Poley JW, Cahen DL, van Hooft JE, Bruno MJ; Dutch Familial Pancreatic Cancer Surveillance Study Group. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut 2021:gutjnl-2020-323611. [PMID: 33820756 DOI: 10.1136/gutjnl-2020-323611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Pin CL, Ryan JF, Mehmood R. Acinar cell reprogramming: a clinically important target in pancreatic disease. Epigenomics. 2015;7:267-281. [PMID: 25942535 DOI: 10.2217/epi.14.83] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
12 Zhan W, Shelton CA, Greer PJ, Brand RE, Whitcomb DC. Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts. Pancreas 2018;47:924-36. [PMID: 30113427 DOI: 10.1097/MPA.0000000000001136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
13 Barbara M, Tsen A, Tenner L, Rosenkranz L. Talking Genes in Breast and Pancreatic Malignancies. Mater Sociomed 2019;31:146-9. [PMID: 31452642 DOI: 10.5455/msm.2019.31.146-149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M;  International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69:7-17. [PMID: 31672839 DOI: 10.1136/gutjnl-2019-319352] [Cited by in Crossref: 93] [Cited by in F6Publishing: 70] [Article Influence: 46.5] [Reference Citation Analysis]
15 Cavanagh H, Rogers KM. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015;13:16. [PMID: 26236408 DOI: 10.1186/s13053-015-0038-x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 11.2] [Reference Citation Analysis]
16 Teo MY, O'Reilly EM. Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 2016;7:738-49. [PMID: 27747088 DOI: 10.21037/jgo.2016.05.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
17 Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, Gregori D, Golan T, Braconi C, Froeling FEM, Milella M, Scarpa A, Pea A, Malleo G, Salvia R, Bassi C, Chang DK, Biankin AV. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. J Clin Oncol 2021;39:2617-31. [PMID: 34197182 DOI: 10.1200/JCO.20.03238] [Reference Citation Analysis]
18 Kroeger PT Jr, Drummond BE, Miceli R, McKernan M, Gerlach GF, Marra AN, Fox A, McCampbell KK, Leshchiner I, Rodriguez-Mari A, BreMiller R, Thummel R, Davidson AJ, Postlethwait J, Goessling W, Wingert RA. The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development. Dev Biol 2017;428:148-63. [PMID: 28579318 DOI: 10.1016/j.ydbio.2017.05.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
19 Starska K, Forma E, Nowacka-zawisza M, Lewy-trenda I, Ciesielski P, Pietruszewska W, Skóra M, Bryś M. The c.*229C > T gene polymorphism in 3′UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma. Tumor Biol 2016;37:4541-57. [DOI: 10.1007/s13277-015-4276-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 de Mestier L, Danset J, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer 2016;23:T57-67. [DOI: 10.1530/erc-16-0269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
21 Baines A, Martin P, Rorie C. Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. Molecular and Cellular Changes in the Cancer Cell. Elsevier; 2016. pp. 277-320. [DOI: 10.1016/bs.pmbts.2016.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
22 Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, Hruban RH, Cote ML, McWilliams RR, Roberts NJ, Cannon-Albright LA, Li D, Moyes K, Wenstrup RJ, Hartman AR, Seminara D, Klein AP, Petersen GM. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17:569-577. [PMID: 25356972 DOI: 10.1038/gim.2014.153] [Cited by in Crossref: 144] [Cited by in F6Publishing: 122] [Article Influence: 20.6] [Reference Citation Analysis]
23 Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. J Gastroenterol 2021;56:713-21. [PMID: 34255164 DOI: 10.1007/s00535-021-01806-y] [Reference Citation Analysis]
24 Lattanzi W, Ripoli C, Greco V, Barba M, Iavarone F, Minucci A, Urbani A, Grassi C, Parolini O. Basic and Preclinical Research for Personalized Medicine. J Pers Med 2021;11:354. [PMID: 33946634 DOI: 10.3390/jpm11050354] [Reference Citation Analysis]
25 Thompson ED, Roberts NJ, Wood LD, Eshleman JR, Goggins MG, Kern SE, Klein AP, Hruban RH. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol 2020;33:2544-63. [PMID: 32704031 DOI: 10.1038/s41379-020-0629-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
26 Corral JE, Mareth KF, Riegert-Johnson DL, Das A, Wallace MB. Diagnostic Yield From Screening Asymptomatic Individuals at High Risk for Pancreatic Cancer: A Meta-analysis of Cohort Studies. Clin Gastroenterol Hepatol. 2019;17:41-53. [PMID: 29775792 DOI: 10.1016/j.cgh.2018.04.065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
27 Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology 2019;156:2041-55. [PMID: 30660730 DOI: 10.1053/j.gastro.2018.12.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
28 Lu C, Xu CF, Wan XY, Zhu HT, Yu CH, Li YM. Screening for pancreatic cancer in familial high-risk individuals: A systematic review. World J Gastroenterol. 2015;21:8678-8686. [PMID: 26229410 DOI: 10.3748/wjg.v21.i28.8678] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
29 Stoffel EM, Mckernin SE, Brand R, Canto M, Goggins M, Moravek C, Nagarajan A, Petersen GM, Simeone DM, Yurgelun M, Khorana AA. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. JCO 2019;37:153-64. [DOI: 10.1200/jco.18.01489] [Cited by in Crossref: 48] [Cited by in F6Publishing: 15] [Article Influence: 24.0] [Reference Citation Analysis]
30 Faraoni I, Graziani G. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel) 2018;10:E487. [PMID: 30518089 DOI: 10.3390/cancers10120487] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 26.3] [Reference Citation Analysis]
31 Stoffel EM, McKernin SE, Khorana AA. Evaluating Susceptibility to Pancreatic Cancer: ASCO Clinical Practice Provisional Clinical Opinion Summary. J Oncol Pract. 2019;15:108-111. [PMID: 30589608 DOI: 10.1200/jop.18.00629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
32 Lucas AL, Kastrinos F. Screening for Pancreatic Cancer. JAMA 2019;322:407-8. [PMID: 31386115 DOI: 10.1001/jama.2019.9690] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
33 Yurgelun MB. Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net. JCO 2017;35:3375-7. [DOI: 10.1200/jco.2017.74.7535] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]